EDWARDS COMMITTEE WILL HEAR HHS ASSISTANT SECRETARY JAMES MASON
EDWARDS COMMITTEE WILL HEAR HHS ASSISTANT SECRETARY JAMES MASON at its Dec. 17-18 meeting evaluate the role of FDA within the framework of HHS. In addition, James MacRae, acting administrator and deputy for the Office of Management and Budget's Office of Information and Regulatory Affairs, will discuss OMB's role in reviewing FDA regulations. Formally named the Advisory Committee on the Food and Drug Administration, the panel will convene at the Holiday Inn Capitol Hill in Washington, D.C. beginning at 8:30 a.m. on each day. The meeting is open to the public. The committee also will hear presentations on the results of recent meetings by its three subcommittees on drugs; medical devices; and food, cosmetics and veterinary medicine. FDA resource issues will be discussed by FDA Associate Commissioners for Management and Operations Sharon Smith Holston and Planning and Evaluation Gerald Barkdoll, PhD, and by Booz-Allen & Hamilton's Mary Jo Veverka. Booz Allen is conducting a pro bono review of FDA resource and management systems needs ("The Pink Sheet" Oct. 1, p. 17). In the afternoon, the committee agenda includes panels on FDA enforcement activities and field operations. The enforcement panel will include: Associate Commissioner for Regulatory Affairs Ron Chesemore; Office of Regulatory Affairs Enforcement Office Director Alan Hoeting; FDA Chief Counsel Margaret Jane Porter; Justice Department Office of Consumer Litigation, Civil Division, Director John Fleder; and House Energy & Commerce/Oversight Subcommittee staff investigator David Nelson. Field operations will be discussed by FDA Midwest Regional Food and Drug Director Burton Love and Mid-Atlantic District Director Thomas Hooker. The meeting will conclude with a discussion by the full committee of the "cross-cutting" issues revealed by the subcommittee reports and other presentations as the panel considers its future activities. That discussion will include presentations from subcommittee chairs Frank Samuel, Sherwin Gardner and Lawrence Horowitz, MD.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth